The acquisition will provide Ortho-Clinical Diagnostics, a Johnson & Johnson company, with access to a high performance technology platform – currently in development in this rapidly growing area of diagnostics – that complements its clinical laboratory, immunohematology and donor screening businesses.
As a result of the acquisition, Johnson & Johnson expects to incur an estimated one-time after-tax charge of approximately $40 million during the second quarter of 2008 related to the expensing of in-process R&D.
Mark Straley, worldwide commercial president Of Ortho-Clinical Diagnostics, said: “This acquisition is a strategic opportunity to develop a point-of-care channel. We’re committed to bringing novel assays and existing tests closer to the patient and delivering information to health care professionals when and where they need it.”